These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24770536)

  • 1. [Avastin-Lucentis: off-label and surroundings].
    Messori A
    Recenti Prog Med; 2014 Apr; 105(4):137-40. PubMed ID: 24770536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.
    Prescrire Int; 2015 Sep; 24(163):201-4. PubMed ID: 26417625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why using Avastin for eye disease is so difficult.
    Torjesen I
    BMJ; 2012 May; 344():e3012. PubMed ID: 22549057
    [No Abstract]   [Full Text] [Related]  

  • 4. The off-label use of medication: the latest on the Avastin - Lucentis debacle.
    Jansen RM
    Med Law; 2013 Mar; 32(1):65-77. PubMed ID: 23781765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minister rules out use of Avastin over Lucentis for wet AMD.
    Kmietowicz Z
    BMJ; 2015 Apr; 350():h2050. PubMed ID: 25882175
    [No Abstract]   [Full Text] [Related]  

  • 6. [Age-related visual loss].
    Neubauer AS; Kernt M
    MMW Fortschr Med; 2013 Feb; 155(2):36-7. PubMed ID: 23573743
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration.
    Landa G; Amde W; Doshi V; Ali A; McGevna L; Gentile RC; Muldoon TO; Walsh JB; Rosen RB
    Ophthalmologica; 2009; 223(6):370-5. PubMed ID: 19590252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
    Hawkes N
    BMJ; 2012 May; 344():e3275. PubMed ID: 22573655
    [No Abstract]   [Full Text] [Related]  

  • 9. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
    Abouammoh M; Sharma S
    Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab versus ranibizumab: why are we not playing the joker?
    Banfi R; Attanasio F; Palazzi N; Colombini S; Falai T; Cecchi M; Virgili G
    Int J Clin Pharm; 2013 Aug; 35(4):507-9. PubMed ID: 23625322
    [No Abstract]   [Full Text] [Related]  

  • 11. A clearer view of evidence in treating macular degeneration: off-label policies and independent research.
    Formoso G; Marata AM; Magrini N; Bero L
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):ED000090. PubMed ID: 25228121
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
    J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer drug offers effective, cheaper option for AMD.
    Stephenson J
    JAMA; 2011 May; 305(20):2053-4. PubMed ID: 21610231
    [No Abstract]   [Full Text] [Related]  

  • 15. Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?
    Ziemssen F; Grisanti S; Bartz-Schmidt KU; Spitzer MS
    Drugs Aging; 2009; 26(4):295-320. PubMed ID: 19476398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.
    Stepien KE; Rosenfeld PJ; Puliafito CA; Feuer W; Shi W; Al-Attar L; Dubovy SR; Murray TG; Davis JL; Lee WH; Schwartz SG; Smiddy WE; Berrocal AM; Flynn HW
    Retina; 2009 Sep; 29(8):1067-73. PubMed ID: 19696701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectivity and safety of bevacizumab intravitreal injections for exudative age-related macular degeneration treatment--6 months observations].
    Małgorzata F
    Klin Oczna; 2010; 112(7-9):213-6. PubMed ID: 21121123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.
    Torjesen I
    BMJ; 2013 Jul; 347():f4678. PubMed ID: 23881948
    [No Abstract]   [Full Text] [Related]  

  • 19. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements.
    Shah AR; Del Priore LV
    Br J Ophthalmol; 2009 Aug; 93(8):1027-32. PubMed ID: 19429594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.
    Silver J
    JAMA; 2014 Jul; 312(1):23-4. PubMed ID: 24860863
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.